| Page 27 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management"

Author(s): 
Mrinal M Patnaik, Ayalew Tefferi
Primary Author: 
Patnaik M
Journal Title: 
American Journal of Hematology
Original Publication Date: 
Mar 2021

Disease overview: Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include

Bone Marrow Disease(s): 

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

Author(s): 
Grunwald MR, Zhang MJ, Elmariah H, Johnson MH, St Martin A, Bashey A, Battiwalla M, Bredeson CN, Copelan E, Cutler CS, George BR, Gupta V, Kanakry C, Mehta RS, Milano F, Mussetti A, Nakamura R, Nishihori T, Saber W, Solh M, Weisdorf DJ, Eapen M
Primary Author: 
Grunwald MR
Journal Title: 
Blood Advances
Original Publication Date: 
Feb 2021

We compared outcomes in 603 patients with myelodysplastic syndrome (MDS) after HLA-haploidentical relative (n = 176) and HLA-matched unrelated (n = 427) donor hematopoietic cell transplantation (HCT) from 2012 to 2017, using the Center for International Blood and Marrow Transplant Research database. All transplantations used reduced-intensity conditioning regimens.

Bone Marrow Disease(s): 

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Author(s): 
Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, Hussaini M, Talati C, Sweet KL, Lancet JE, Padron E, List AF, Sallman DA
Primary Author: 
Hunter AM
Journal Title: 
Blood Advances
Original Publication Date: 
Feb 2021

Hypomethylating agents (HMAs) are widely used in the treatment of

Bone Marrow Disease(s): 

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

Author(s): 
Cluzeau T, Sebert M, Rahmé R, Cuzzubbo S, Lehmann-Che J, Madelaine I, Peterlin P, Bève B, Attalah H, Chermat F, Miekoutima E, Rauzy OB, Recher C, Stamatoullas A, Willems L, Raffoux E, Berthon C, Quesnel B, Loschi M, Carpentier AF, Sallman DA, Komrokji R,
Primary Author: 
Cluzeau T
Journal Title: 
Journal of clinical oncology: official journal of the American Society Clinical Oncology
Original Publication Date: 
Feb 2021

Purpose: TP53-mutated (TP53m)

Bone Marrow Disease(s): 

Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantat

Author(s): 
Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B,
Primary Author: 
Saberian C
Journal Title: 
Journal for immunotherapy of cancer
Original Publication Date: 
Feb 2021

Background: Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction. However, a major concern for the use of ICIs after alloHCT is the increased risk of

Bone Marrow Disease(s): 

Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria

Author(s): 
Carmelo Gurnari, Amy C Graham, Alexey Efanov, Simona Pagliuca, Jibran Durrani, Hassan Awada, Bhumika J Patel, Alan E Lichtin, Valeria Visconte, Mikkael A Sekeres, Jaroslaw P Maciejewski
Primary Author: 
Gurnari C
Journal Title: 
Blood cells, molecules and diseases
Original Publication Date: 
Mar 2021

While red blood cells (RBCs) and granulocytes have been more studied, platelets and reticulocytes are not commonly used in

Bone Marrow Disease(s): 

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome

ABSTRACT

PURPOSE
Patients with myelodysplastic syndrome (MDS) are at risk of relapse after allogeneic hematopoietic cell transplantation. The utility of ultra-deep genomic testing to predict and the impact of conditioning intensity to prevent MDS relapse are unknown.

Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: a prospective study of feasibility, safety, and healthcare resource use

Abstract
Background
We evaluated feasibility, safety, and total resource use of subcutaneous immunoglobulin (SCIG) in a pilot study of patients who underwent allogeneic hematopoietic cell transplant (HCT) over a 6-month period.